IDT Biologika is a global contract development and manufacturing organization for vaccines, cell & gene therapeutics, oncolytic viruses, viral vectors and recombinant proteins for sterile liquid and lyophilized products. This includes end-to-end services from process development through drug substance manufacturing up to BSL-3, sterile liquid dosage filling & lyophilization, labeling & packaging to quality control & analytics.
We offer clients in B2B business a single source CDMO partner at our sites in Germany and the USA, with seamless end-to-end solutions and the ability to nimbly scale projects from development through to commercialization. IDT Biologika handles every step in manufacturing and packaging of small clinical batches and large-scale commercial products.
Our fully integrated services at our sites in Germany and the USA are underscored by our commitment to quality and operational excellence that flows through our best-in-class process and cGMP (up to BSL3) manufacturing capabilities meeting FDA, EMA and ANVISA standards.
If you chose IDT Biologika, you receive reliable high quality services on products because we have the quality and supply mindset underlining the customer needs for speed to market.
We supply our client’s products in vials, pre-filled syringes, autoinjectors or as combination products.
IDT Biologika is unique in its ability to accommodate the development, testing and manufacture of products for the world’s leading biopharmaceutical companies. Many human vaccines developed by IDT Biologika, together with international partners, are already in use, fighting infectious diseases such as COVID-19, tuberculosis, AIDS, malaria, dengue, ebola and chikungunya.
For more information see www.idt-biologika.com.